Abivax S.A.

Abivax S.A.

AAVXF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$6.92B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Abivax S.A.Abivax S.A.-16.8--133%--
$7.68

Current Fair Value

90.9% downside

Overvalued by 90.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$6.92 Billion
Enterprise Value$6.54 Billion
Earnings per Share$-4.83
Beta-0.21
Outstanding Shares79,647,974

Return

Return on Equity-133.12%ROE
Return on Assets-105.49%
Return on Invested Capital-104.99%

Valuation & Multiples

P/E Ratio-16.79P/E Ratio
PEG-101.66PEG
Price to Sales-Price to Sales
Price to Book Ratio21.2Price to Book Ratio
Enterprise Value to Revenue3264.07
Enterprise Value to EBIT-15.95
Enterprise Value to Net Income-14
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 21, 2026
EPS
-$1.68
Est. -$0.92
Revenue
$1.37 M
Est. $796,823

Next Earnings Call

Expected Date
December 14, 2026
EPS Estimate
-$0.86
Consensus analyst estimate
Revenue Estimate
$892,477
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Abivax

69 employees
CEO: Marc de Garidel

Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectio...